Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1 study includes late-line patients and patients with AR-v7 splice variants for whom there are no approved therapies

FT-7051 is a selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300) and a co-activator of androgen receptor

In prostate cancer cell lines in vitro, FT-7051 demonstrated inhibition of AR-dependent gene expression and a reduction in androgen receptor expression; also demonstrated antiproliferative activity in AR-positive prostate cancer cell lines, including resistance variant AR-v7 positive models

WATERTOWN, MA, USA I January 20, 2021 IForma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating FT-7051, a selective inhibitor of CBP/p300, a known co-activator of the androgen receptor (AR) in men with metastatic castration-resistant prostate cancer (mCRPC).

“While a patient with mCRPC may initially respond to standard anti-androgen therapies, a significant unmet need persists since nearly all patients ultimately become resistant to these treatments,” said David N. Cook, Ph.D., chief scientific officer of Forma Therapeutics. “Initiating enrollment in this Phase 1 trial is an important step toward our goal of providing mCRPC patients with an additional therapeutic option to treat this severe illness.”

Study Design

The Phase 1 trial is a multicenter, open-label evaluation of the safety and tolerability, preliminary anti-tumor activity (PSA and radiographic responses), and pharmacokinetics/pharmacodynamics (PK/PD) of FT-7051 in men with mCRPC who have progressed despite prior therapy and have been treated with at least one potent anti-androgen therapy. This is an adaptive trial design, intended to accelerate the escalation to potentially therapeutic doses and yield important safety information. More information about this trial may be accessed at Clinicaltrials.gov (identifier: NCT04575766).

About FT-7051

FT-7051 is a selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300) and a co-activator of androgen receptor (AR). In prostate cancer cell lines in vitro, FT-7051 demonstrated inhibition of AR-dependent gene expression and reductions in androgen receptor expression. FT-7051 also demonstrated antiproliferative activity in AR-positive prostate cancer cell lines, including resistance variant AR-v7 positive models.

About Metastatic Castration-resistant Prostate Cancer

Prostate cancer is the second leading cause of cancer death for men in the U.S., and mCRPC is the most advanced form of this disease. Prostate cancer cell growth is driven by activity of the androgen receptor (AR). Primary treatments of mCRPC include therapies that reduce androgen synthesis or inhibit androgen binding and activation of the AR. Studies have shown that approximately 20% to 40% of mCRPC patients demonstrate primary resistance to enzalutamide and abiraterone acetate, two commonly used therapies, and virtually all patients who demonstrate initial clinical responses eventually acquire resistance. There are currently no approved therapies specifically aimed at mCRPC over-expressing AR variants, including AR-v7; therefore, a novel inhibitor of AR co-activator CBP/p300 may play a role in the suppression of mCRPC driven by AR aberrations.

About Forma Therapeutics

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.

SOURCE: Forma Therapeutics

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top